Several of our mAbs belonging to the mAb 2164H5 group also allowed us to immunolocalize cell surface-shed NG2/CSPG4 fragments 'in situ' in both glioblastoma and foetal brain VBM and stromal ECM. Here, CSPG4 is linked to glioblastoma.